Abstract:Liver abscesses in feedlot cattle are a polymicrobial infection with Fusobacterium necrophorum and Trueperella pyogenes as the primary and secondary etiologic agents, respectively. Cattle with liver abscesses do not exhibit clinical signs and the abscesses are detected only at slaughter. The objective was to conduct metabolomics analysis of purulent materials of liver abscesses to identify biochemicals. Liver abscesses from crossbred cattle (n=24) and Holstein steers (n=24), each fed high-grain finishing diet … Show more
“…Antibiotic prophylaxis has effectively reduced the severity of liver abscesses [8], with the US Feed Additive Compendium listing five antimicrobials currently approved for use to prevent this disease in cattle [9]. Among these drugs, tylosin is the most effective antibiotic, but even it does not entirely prevent liver abscesses [8,10]. In addition, there has been a surge in antibiotic resistance in recent years, a process that we now know is inevitable [11].…”
Section: Introductionmentioning
confidence: 99%
“…These rising resistance rates, combined with increased public health concern about the use of antibiotics for growth promotion in food animals and the growing consumer demand for "No added antibiotics", have driven the search for viable alternatives to antibiotics. Given that liver abscess is diagnosed only at the late stages of the disease, leading to poor prognoses for infected animals [10,12], the best option is likely to be the development of a potent vaccine that effectively prevents F. necrophorum infection in cattle.…”
Fusobacterium necrophorum, an anaerobic Gram-negative pathogen, causes necrotic cattle infections, impacting livestock health and the US feedlot industry. Antibiotic administration is the mainstay for treating F. necrophorum infections, although resistance hampers their effectiveness. Vaccination, especially targeting outer membrane proteins (OMPs) due to their antigenic properties and host specificity, offers an alternative to antibiotics. This study identified high-binding-affinity adhesion proteins from F. necrophorum using binding and pull-down assays with bovine adrenal gland endothelial cells (EJG). Four OMP candidates (17.5 kDa/OmpH, 22.7 kDa/OmpA, 66.3 kDa/cell surface protein (CSP), and a previously characterized 43 kDa OMP) were expressed as recombinant proteins and purified. Rabbit polyclonal antibodies to recombinant OMPs were generated, and their ability to inhibit bacterial binding in vitro was assessed. The results show that treatment with individual polyclonal antibodies against 43 kDa significantly inhibited bacterial adhesion, while other antibodies were less potent. However, combinations of two or more antibodies showed a more prominent inhibitory effect on host-cell adhesion. Thus, our findings suggest that the identified OMPs are involved in fusobacterial attachment to host cells and may have the potential to be leveraged in combination for vaccine development. Future in vivo studies are needed to validate their roles and test the feasibility of an OMP-based subunit vaccine against fusobacterial infections.
“…Antibiotic prophylaxis has effectively reduced the severity of liver abscesses [8], with the US Feed Additive Compendium listing five antimicrobials currently approved for use to prevent this disease in cattle [9]. Among these drugs, tylosin is the most effective antibiotic, but even it does not entirely prevent liver abscesses [8,10]. In addition, there has been a surge in antibiotic resistance in recent years, a process that we now know is inevitable [11].…”
Section: Introductionmentioning
confidence: 99%
“…These rising resistance rates, combined with increased public health concern about the use of antibiotics for growth promotion in food animals and the growing consumer demand for "No added antibiotics", have driven the search for viable alternatives to antibiotics. Given that liver abscess is diagnosed only at the late stages of the disease, leading to poor prognoses for infected animals [10,12], the best option is likely to be the development of a potent vaccine that effectively prevents F. necrophorum infection in cattle.…”
Fusobacterium necrophorum, an anaerobic Gram-negative pathogen, causes necrotic cattle infections, impacting livestock health and the US feedlot industry. Antibiotic administration is the mainstay for treating F. necrophorum infections, although resistance hampers their effectiveness. Vaccination, especially targeting outer membrane proteins (OMPs) due to their antigenic properties and host specificity, offers an alternative to antibiotics. This study identified high-binding-affinity adhesion proteins from F. necrophorum using binding and pull-down assays with bovine adrenal gland endothelial cells (EJG). Four OMP candidates (17.5 kDa/OmpH, 22.7 kDa/OmpA, 66.3 kDa/cell surface protein (CSP), and a previously characterized 43 kDa OMP) were expressed as recombinant proteins and purified. Rabbit polyclonal antibodies to recombinant OMPs were generated, and their ability to inhibit bacterial binding in vitro was assessed. The results show that treatment with individual polyclonal antibodies against 43 kDa significantly inhibited bacterial adhesion, while other antibodies were less potent. However, combinations of two or more antibodies showed a more prominent inhibitory effect on host-cell adhesion. Thus, our findings suggest that the identified OMPs are involved in fusobacterial attachment to host cells and may have the potential to be leveraged in combination for vaccine development. Future in vivo studies are needed to validate their roles and test the feasibility of an OMP-based subunit vaccine against fusobacterial infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.